EP3658137A4 - Cannabinoid composition having an optimized fatty acid excipient profile - Google Patents

Cannabinoid composition having an optimized fatty acid excipient profile Download PDF

Info

Publication number
EP3658137A4
EP3658137A4 EP18838855.7A EP18838855A EP3658137A4 EP 3658137 A4 EP3658137 A4 EP 3658137A4 EP 18838855 A EP18838855 A EP 18838855A EP 3658137 A4 EP3658137 A4 EP 3658137A4
Authority
EP
European Patent Office
Prior art keywords
fatty acid
cannabinoid composition
acid excipient
profile
optimized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18838855.7A
Other languages
German (de)
French (fr)
Other versions
EP3658137A1 (en
Inventor
Basil Adil SHAABAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2018/044226 external-priority patent/WO2019023668A1/en
Publication of EP3658137A1 publication Critical patent/EP3658137A1/en
Publication of EP3658137A4 publication Critical patent/EP3658137A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18838855.7A 2017-07-27 2018-07-27 Cannabinoid composition having an optimized fatty acid excipient profile Withdrawn EP3658137A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762537738P 2017-07-27 2017-07-27
PCT/US2018/044226 WO2019023668A1 (en) 2017-07-27 2018-07-27 Cannabinoid composition having an optimized fatty acid excipient profile

Publications (2)

Publication Number Publication Date
EP3658137A1 EP3658137A1 (en) 2020-06-03
EP3658137A4 true EP3658137A4 (en) 2020-06-03

Family

ID=70412433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18838855.7A Withdrawn EP3658137A4 (en) 2017-07-27 2018-07-27 Cannabinoid composition having an optimized fatty acid excipient profile

Country Status (1)

Country Link
EP (1) EP3658137A4 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526752B1 (en) * 2015-02-12 2016-12-27 Gary Allen Lowe Composition of cannabinoids, odorous volatile compounds, and emu oil for topical application, and a method for cannabinoid transdermal delivery
WO2017045053A1 (en) * 2015-09-18 2017-03-23 Prati, Donaduzzi & Cia Ltda Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526752B1 (en) * 2015-02-12 2016-12-27 Gary Allen Lowe Composition of cannabinoids, odorous volatile compounds, and emu oil for topical application, and a method for cannabinoid transdermal delivery
WO2017045053A1 (en) * 2015-09-18 2017-03-23 Prati, Donaduzzi & Cia Ltda Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AQUINO-BOLAÑOS ELIA N. ET AL: "Fatty acids profile of oil from nine varieties of Macadamia nut", INTERNATIONAL JOURNAL OF FOOD PROPERTIES, vol. 20, no. 6, 3 June 2017 (2017-06-03), US, pages 1262 - 1269, XP055804027, ISSN: 1094-2912, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/10942912.2016.1206125?needAccess=true> [retrieved on 20210513], DOI: 10.1080/10942912.2016.1206125 *
See also references of WO2019023668A1 *
SUZANNE MASHTOUB ET AL: "Emu oil expedites small intestinal repair following 5-fluorouracil-induced mucositis in rats", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 238, no. 11, 18 September 2013 (2013-09-18), GB, pages 1305 - 1317, XP055685641, ISSN: 1535-3702, DOI: 10.1177/1535370213493718 *

Also Published As

Publication number Publication date
EP3658137A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
EP3703672A4 (en) Cannabinoid formulations
EP3429580A4 (en) Terpene-enriched cannabinoid composition
EP3697376B8 (en) Composition
EP3346997A4 (en) Bioorthogonal compositions
EP3722358A4 (en) Composition
EP3302437B8 (en) Stable cannabinoid formulations
EP3240555A4 (en) Multi-supplement compositions
EP3342819A4 (en) Curable composition
AU2016291708B2 (en) Plinabulin compositions
EP3462885A4 (en) Stable cannabinoid formulations
EP3407855A4 (en) Stable antioxidant compositions
EP3613779A4 (en) Curable composition
EP3566262A4 (en) Low profile antenna - conformal
EP3367997A4 (en) Novel occlusive formulations
EP3327050A4 (en) Curable composition
EP3705531A4 (en) Curable composition
EP3697866A4 (en) Etching compositions
EP3584364A4 (en) Composition
EP3702377A4 (en) Curable composition
EP3705528A4 (en) Curable composition
EP3705529A4 (en) Curable composition
EP3630883A4 (en) Curable compositions
EP3716966A4 (en) Alpha keto acid compositions for treating hypo-albuminemia
EP3478296A4 (en) Phosopholipid compositions
EP3373928A4 (en) Novel formulations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200227

A4 Supplementary search report drawn up and despatched

Effective date: 20200429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210519

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221213